Imunon
$0.91
8
-$0-0.07% Thursday 19:36
Statistics
Day High
-
Day Low
0.91
52W High
1.72
52W Low
0.84
Volume
23,839
Avg. Volume
22,817
Mkt Cap
8.55M
P/E Ratio
-0.29
Dividend Yield
-
Dividend
-
Upcoming
Earnings
14NovConfirmed
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
-3.62
-2.54
-1.45
-0.37
Expected EPS
-0.66
Actual EPS
-0.37
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMNN. It's not an investment recommendation.
Analyst Ratings
12$Average Price Target
The highest estimate is $12.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Show more...
CEO
Michael Tardugno
Employees
27
Country
US
ISIN
US15117N6022
WKN
000A3DWEJ